Liver transplantation for fulminant hepatitis related to nevirapine therapy
✍ Scribed by Sophie Buyse; Eric Vibert; Mylène Sebagh; Teresa Antonini; Philippe Ichai; Denis Castaing; Didier Samuel; Jean-Charles Duclos-Vallée
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 270 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20985
No coin nor oath required. For personal study only.
✦ Synopsis
Drug-induced hepatotoxicity is an important cause of hepatocellular injury. Non-nucleoside retroviral transcriptase inhibitors are known to cause hepatotoxicity. We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation.
📜 SIMILAR VOLUMES
s an indication for transplantation, fulminant A hepatic failure (FHF) accounts for approximately 7% of the liver transplantations currently performed in the United States and This percentage is very small in comparison with the number of transplants performed for chronic liver disease, but FHF domi
Standard antituberculous therapy including isoniazid, rifampin, ethambutol, and pyrazinamide is widely used for the treatment of active tuberculosis. Its most important side effect is hepatotoxicity, ranging from asymptomatic transaminitis to fulminant hepatic failure. A 19-year-old woman was admitt
Since the introduction of techniques to reliably identify antibody to the hepatitis C virus and quantitation of hepatitis C virus, there has been an increasing interest in the behavior of chronic hepatitis C infection with liver transplantation. Ninety-seven patients with chronic active hepatitis C